Navigation Links
MEI Pharma to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Date:9/17/2013

ients with solid refractory tumors are anticipated in October 2013. In September 2013, the Company further expanded its pipeline of drug candidates with the acquisition of PWT143, a highly selective PI3-kinase delta inhibitor. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-t
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... million bringing Q3 orders to date to $5 million. The ... America . "We continue to see new ... CEO. "With these orders, our backlog has climbed to over ... BIOREM is a leading clean technology company that designs, manufactures ...
(Date:9/23/2014)... Mass. (PRWEB) September 23, 2014 Cambridge ... by Semantic Web technology, was named in the recent ... Gartner, Inc. , The report details key insights ... , According to Gartner analysts Michael Shanler and ... accelerate innovation activities, expose complex relationships with scientific stakeholders, ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 Dr. ... my third book on healthcare offers a three phase ... 21st century healthcare delivery system that would go far ... state’s responsibility regarding the delivery of healthcare.” , “Every ... safety has failed to provide discernable progress throughout that ...
(Date:9/22/2014)... 2014 Pearl's Premium Ultra Low Maintenance ... tolerant grass seed this week with the release of ... coincides with the fact that it is time to ... believe. , As of the date 6/4/13, Pearl's ... by industry experts and the media including: The ...
Breaking Biology Technology:Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... 3 Human Genome Sciences, Inc. (Nasdaq: HGSI ... 26,697,250 newly issued shares of its common stock at a ... 3,482,250 shares sold upon exercise by the underwriters of their ... the Company from the offering are approximately $356.7 million, after ...
... Aug. 3 Known medically as atopic dermatitis (AD), ... Scratching the affected area of skin may result ... and crusting of the skin.(2) Immuno-modulators called topical calcineurin ... with mild, moderate or severe eczema(3) who fail to ...
... Md., Aug. 3 Micromet, Inc. (Nasdaq: ... for the treatment of cancer, inflammation and autoimmune diseases, ... from the European Medicines Agency (EMEA) for BiTE antibody ... is a novel therapeutic antibody that activates a patient,s ...
Cached Biology Technology:Human Genome Sciences Announces Closing of Public Offering 2Human Genome Sciences Announces Closing of Public Offering 3Five Questions About Protopic (tacrolimus) Ointment 2Five Questions About Protopic (tacrolimus) Ointment 3Five Questions About Protopic (tacrolimus) Ointment 4Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 4
(Date:9/22/2014)... at the University of Chicago have shown that after ... only a handful of pathogenic microbe species remain behind ... and discovered that some can become deadly when provoked ... illness. , The findings, published in mBio , ... Microbiology, may lead to better monitoring and treatment of ...
(Date:9/22/2014)... STATION The smell of cut grass in recent ... signalling distress, but new research says the aroma also ... is need for protection, the plant signals the environment ... recognized as a feeding queue for parasitic wasps to ... lay eggs in the pest insect," said Dr. Michael ...
(Date:9/22/2014)... in a plant,s biological clock one that modulates ... , Transcription factors, or genetic switches, drive gene expression ... light, rain, soil quality, or even animals grazing on ... one, called FBH1, that reacts to temperature tweaking ... keeping it on a consistent track. , "Temperature helps ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3Genetic switch regulates a plant's internal clock based on temperature 2
... While patients hospitalized for a heart attack have long ... analysis by researchers from the Duke Clinical Research Institute ... percent higher risk of dying. , The researchers call ... Meanwhile, they advise cardiologists to begin treatment with sufficient ...
... by fruit fly geneticists for more than a decade ... in mice. , Writing in the May 6 edition ... a streamlined method for creating a "genetic mosaic mouse"--a ... clusters of cells with mutated genes. , The new ...
... statistical method, described in the open-access journal PLoS Biology, ... locations in the genome that influence a particular physical ... by John Storey, Joshua M. Akey, and Leonid Kruglyak, ... them identify all the genomic elements that produce specific ...
Cached Biology News:Morphine for Chest Pain Increases Death Risk 2Morphine for Chest Pain Increases Death Risk 3Mosaic mouse technique offers a powerful new tool to study diseases and genetics 2Mosaic mouse technique offers a powerful new tool to study diseases and genetics 3Improved statistical tools reveal many linked loci 2
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... real-time PCR detection system uses a fixed ... nm) and a photomultiplier tube for fluorescence ... built on an DNA Engine thermal cycler ... This item includes the thermal cycler, 96-well ...
... The MyiQ detection system is used ... I, FAM, VIC, TET, or JOE fluorophores ... simultaneous collection of fluorescence data from 96 ... quantitation, and customizable end-point analysis. The system ...
... Microdissection , CapSure HS and CapSure Macro ... extraction of populations of pure cells from ... Capture Microdissection., Ensure the Integrity of ... All CapSure LCM Caps have a patented ...
Biology Products: